Close Menu

SEATTLE (GenomeWeb) – A new analysis from Invitae suggests a significant proportion of informative, pathogenic cancer risk variants may be missed by focusing germline genetic tests in cancer patients on relatively few genes with potential ties to an individual's cancer type.

Invitae's Edward Esplin outlined results from the study during a session on cancer risk assessment and management at the American College of Medical Genetics and Genomics annual meeting here on Friday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.